4-Bromo-2-methoxyaniline, 98%, Thermo Scientific Chemicals
4-Bromo-2-methoxyaniline, 98%, Thermo Scientific Chemicals
4-Bromo-2-methoxyaniline, 98%, Thermo Scientific Chemicals
Thermo Scientific Chemicals

4-Bromo-2-methoxyaniline, 98%, Thermo Scientific Chemicals

製品番号(カタログ番号)数量
H61454.06
または、製品番号H61454-06
5 g
製品番号(カタログ番号) H61454.06
または、製品番号H61454-06
価格(JPY)
-
数量:
5 g
一括またはカスタム形式をリクエストする
化学物質識別子
CAS59557-91-4
IUPAC Name4-bromo-2-methoxyaniline
Molecular FormulaC7H8BrNO
InChI KeyWRFYIYOXJWKONR-UHFFFAOYSA-N
SMILESCOC1=C(N)C=CC(Br)=C1
さらに表示
Assay (HPLC)>97.5%
4-Bromo-2-methoxyaniline is used as a reagent in the synthesis of 3,5-diamino-1,2,4-triazole ureas as potent anaplastic lymphoma kinase (ALK) inhibitors. It is also used as a reagent in the synthesis of chroman-3-amides as potent Rho kinase inhibitors. It is an important raw material and intermediate used in organic synthesis, pharmaceuticals, agrochemicals and dyestuff fields.

This Thermo Scientific Chemicals brand product was originally part of the Alfa Aesar product portfolio. Some documentation and label information may refer to the legacy brand. The original Alfa Aesar product / item code or SKU reference has not changed as a part of the brand transition to Thermo Scientific Chemicals.

Applications
4-Bromo-2-methoxyaniline is used as a reagent in the synthesis of 3,5-diamino-1,2,4-triazole ureas as potent anaplastic lymphoma kinase (ALK) inhibitors. It is also used as a reagent in the synthesis of chroman-3-amides as potent Rho kinase inhibitors. It is an important raw material and intermediate used in organic synthesis, pharmaceuticals, agrochemicals and dyestuff fields.

Solubility
Soluble in methanol.

Notes
Keep container tightly sealed. Store in cool, dry conditions in well sealed containers. Incompatible with oxidizing agents.
RUO – Research Use Only

General References:

  1. P. S. Portoghese.; H. Nagase.; A. W. Lipkowski.; D. L. Larson.; A. E. Takemori. Binaltorphimine-related bivalent ligands and their .kappa. opioid receptor antagonist selectivity [Erratum to document cited in CA108(17):150771q]. J. Med. Chem. 1988, 31 (10), 2056-2056.
  2. Kate M. Clapham.; Julia Bardos.; M. Raymond V. Finlay.; Bernard T. Golding.; Edward J. Griffen.; Roger J. Griffin.; Ian R. Hardcastle.; Keith A. Menear.; Attilla Ting.; Paul Turner.; Gail L. Young.; Celine Cano. DNA-dependent protein kinase (DNA-PK) inhibitors: Structure-activity relationships for O-alkoxyphenylchromen-4-one probes of the ATP-binding domain. Bioorganic & Medicinal Chemistry Letters. 2011, 21 (3), 966-970.